



Resmetirom and Obeticholic Acid for Non-Alcoholic Steatohepatitis: Effectiveness and Value

Friday • April 28, 2023 • 10:00 AM – 4:00 PM CDT

Virtual Event – Zoom Webinar

https://us02web.zoom.us/webinar/register/WN_z9p_kqEISRC6JfV_CBBOA

Time (CDT)	Activity
10:00am – 10:20am	Meeting Convened and Opening Remarks Steven D. Pearson, MD, MSc President, ICER
10:20am – 11:00am	Presentation of the Clinical Evidence Jeff Tice, MD Professor of Medicine, University of California, San Francisco
11:00am – 11:40am	Presentation of the Economic Model Kangho Suh, PharmD, PhD Assistant Professor, School of Pharmacy, University of Pittsburgh
11:40am – 12:15pm	Public Comments and Discussion
12:15pm – 12:50pm	Lunch Break
12:50pm – 1:50pm	Midwest CEPAC Vote on Clinical Effectiveness and Value
1:50pm – 2:00pm	Break
2:00pm – 3:30pm	Policy Roundtable
3:30pm – 4:00pm	Reflections from Midwest CEPAC
4:00pm	Meeting Adjourned

ICER Staff and Consultants	
Josh J. Carlson, MPH, PhD , Professor, University of Washington*	Marina Richardson, MSc , Senior Health Economist, ICER*
Janet N. Chu, MD, MPH, MAS , Assistant Professor of Medicine, University of California, San Francisco†	David M. Rind, MD, MSc , Chief Medical Officer, ICER*
Ronald Dickerson, MPH, M.Econ , Research Assistant, University of Washington School of Pharmacy*	Liis Shea, MA , Program Director, ICER*
Shahariar Mohammed Fahim, PhD , Research Lead, Evidence Synthesis, ICER*	Kangho Suh, PharmD, PhD , Assistant Professor, School of Pharmacy, University of Pittsburgh*
Belen Herce-Hagiwara, BA , Research Assistant, Evidence Synthesis, ICER*	Jeffrey A. Tice, MD , Professor of Medicine, University of California, San Francisco*
Becca Piltch, MPP , Program Associate, ICER*	
*No conflicts of interest to disclose, defined as individual health care stock ownership in any health plan or pharmaceutical, biotechnology, or medical device manufacturers, or any health care consultant income or honoraria from health plans or manufacturers.	
†Research support from Gilead on NAFLD identification in Primary Care	

Participating Members of Midwest CEPAC	
Eric Ambrecht, PhD , Associate Professor, St. Louis University Center for Health Outcomes Research, School of Medicine and College for Public Health and Social Justice	Heather Guidone, BCPA , Program Director, Center for Endometriosis Care
Alan Balch, PhD , Chief Executive Officer, Patient Advocate Foundation; The National Patient Advocate Foundation	Jill Johnson, PharmD , Professor, Pharmacy Practice, University of Arkansas for Medical Sciences
Bijan Borah, PhD , Professor of Health Services Research, Mayo Clinic College of Medicine and Science	Timothy McBride, MS, PhD , Professor, Washington University in St. Louis
Gregory Curfman, MD , Executive Editor, JAMA, American Medical Association	Reem Mustafa, MD, MPH, PhD , Professor of Internal Medicine and Population Health, University of Kansas
Sneha Dave, BA , Executive Director, Generation Patient	Kurt Vanden Bosch, PharmD , System Formulary Lead, St. Luke's Health System
Elbert Huang, MD, MPH , Professor of Medicine and Public Health Sciences, University of Chicago	Timothy Wilt, MD, MPH , Professor of Medicine and Public Health, Minneapolis VA Health Care System
Yngve Falck-Ytter, MD , Professor of Medicine, Case Western Reserve University	Stuart Winston, DO , Patient Experience Consultant, Trinity-Health IHA Medical Group
Angela Fleming Brown, MPH , CEO, St. Louis Regional Health Commission	

*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

Policy Roundtable Participant	Conflict of Interest
<p>Danielle Brandman, MD, MAS, Medical Director of Liver Transplantation, Weill Cornell Medicine</p>	<p>Dr. Brandman has received prior research funding from Gilead and Genentech for research in the clinical area of this meeting.</p> <p>Dr. Brandman was previously a Principal investigator on clinical trials involving other drugs for NAFLD.</p>
<p>Stephen Dodge, PharmD, MBA, Senior Vice President, Global Medical Affairs, Madrigal Pharmaceuticals</p>	<p>Dr. Dodge is a full-time employee of Madrigal Pharmaceuticals.</p>
<p>Anthony Grillo, PharmD, Vice President, Express Scripts</p>	<p>Dr. Grillo has equity interests in excess of \$10,000 in Cigna Healthcare.</p> <p>Dr. Grillo is a full-time employee within Cigna/Express Scripts.</p>
<p>Jennifer Martin, PharmD, Deputy Chief Consultant, PBM, Department of Veterans Affairs</p>	<p>No conflicts to disclose.</p>
<p>Kimberly Martinez, Patient Advocate</p>	<p>No conflicts to disclose.</p>
<p>Adnan Said, MD, MS, Professor, Gastroenterology and Hepatology, Director, Metabolic Liver Health Clinic, University of Wisconsin School of Medicine and Public Health</p>	<p>Dr. Said has received consulting support in excess of \$5,000 from Mallinckrodt pharmaceuticals and serves as a Site Principal investigator for the REGENERATE study.</p>